3083-Article Text (primary submission content)-31356-1-10-20210510.pdf (2.15 MB)
Angiotensin receptor blocker losartan inhibits tumor growth of colorectal cancer
Version 2 2023-06-12, 09:51
Version 1 2023-06-09, 23:52
journal contribution
posted on 2023-06-12, 09:51 authored by Milad Hashemzehi, Farzad Rahmani, Mahdieh Khoshakhlagh, Amir Avan, Fereshteh Asgharzadeh, Farnaz Barneh, Reyhaneh Moradi-Marjaneh, Atena Soleimani, Hamid Fiuji, Gordon FernsGordon Ferns, Mikhail Ryzhikov, Mohieddin Jafari, Majid Khazaei, Seyed Mahdi HassanianThe renin-angiotensin system (RAS) is up-regulated in patients with colorectal cancer (CRC) and is reported to be associated with poor prognosis and chemo-resistance. Here we explored the therapeutic potential of targeting RAS in CRC using Losartan, an angiotensin receptor blocker. An integrative-systems biology approach was used to explore a proteome-level dataset of a gene signature that is modulated by Losartan. The anti-proliferative activity of Losartan was evaluated using 2- and 3-dimensional cell culture models. A xenograft model of colon cancer was used to investigate tumor growth with Losartan alone and in combination with 5-FU followed by histological staining (Hematoxylin & Eosin and Masson trichrome staining), biochemical analyses, gene expression analyses by RT-PCR, western blot/IHC, or MMP Gelatin Zymography studies. Effects on cell cycle and cell death were assessed by flow cytometry. Losartan inhibited cell growth and suppressed cell cycle progression, causing an increase in CRC cells in the G1 phase. Losartan significantly reduced tumor growth and enhanced tumor cell necrosis. An impact on the inflammatory response, including up-regulation of pro-inflammatory cytokines and chemokines in CRC cells are potential mechanisms that could partially explain Losartan’s anti-proliferative effects. Moreover, metastasis and angiogenesis were reduced in Losartan-treated mice as observed by inhibited matrix metalloproteinase-2 and -9 activities and decreased tumor vasculature. These data demonstrate the therapeutic potential of combining chemotherapeutic regimens with Losartan to synergistically enhance its activity and target the renin-angiotensin system as a new approach in colorectal cancer treatment.
History
Publication status
- Published
File Version
- Published version
Journal
EXCLI JournalISSN
1611-2156Publisher
IfADoExternal DOI
Volume
20Page range
506-521Department affiliated with
- Division of Medical Education Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-05-17First Open Access (FOA) Date
2021-05-17First Compliant Deposit (FCD) Date
2021-05-17Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC